CytomX Therapeutics, Inc.
CTMXNasdaq
$3.62
↓ -1.2%Jul 17 close · end-of-day
Price
1Y↑ +51.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$641.7M
Enterprise Value
$295.0M
P/E
—
P/S
18.1
P/B
2.0
EV/EBITDA
—
PEG
—
FCF Yield
-12.5%
Dividend Yield
—
Revenue (TTM)
$35.5M
Net Income (TTM)
-$59.1M
Free Cash Flow (TTM)
-$80.2M
Gross Margin
—
Operating Margin
-181.9%
Net Margin
-166.4%
ROE
-18.5%
ROIC
—
Debt / Equity
—
Net Cash
$346.7M
Return 1Y
+52.1%
Company profile
Management & directors
- Ogden ChristopherChief Financial Officer
- Belvin MarciaSVP, Chief Scientific Officer
- Chu Yu-WayeChief Medical Officer
- Mccarthy Sean A.CEO
- Lester RachaelChief Business Officer
Roles derived from SEC Form 4 filings.
Earnings
CTMX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$10.3M↓ -79.9%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $68.4M | $37.3M | $53.2M | $101.2M | $138.1M | $76.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$80.5M | -$116.0M | -$101.3M | -$6.5M | $25.0M | -$22.4M |
| Net income | -$64.8M | -$115.9M | -$99.3M | -$569,000.00 | $31.9M | -$17.4M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | $5.3M | -$119.0M | -$110.8M | -$56.0M | -$86.2M | -$75.6M |
| Free cash flow | $3.0M | -$120.6M | -$112.5M | -$56.9M | -$86.5M | -$75.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -117.7% | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Net margin | -94.7% | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.1M | $33.4M | $38.1M | $50.9M | $18.7M | $6.0M | $663,000.00 | $10.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.5M | $4.1M | $17.7M | $22.6M | -$1.3M | -$15.8M | -$27.9M | -$19.7M |
| Net income | -$6.5M | $5.7M | $18.9M | $23.5M | -$154,000.00 | -$14.2M | -$26.5M | -$18.2M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$19.5M | -$20.7M | -$19.9M | -$21.0M | -$15.8M | -$15.5M | -$23.2M | -$25.5M |
| Free cash flow | -$19.6M | -$20.7M | -$20.0M | -$21.2M | -$15.8M | -$15.7M | -$23.4M | -$25.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -33.7% | 12.3% | 46.4% | 44.4% | -6.9% | -264.4% | -4212.8% | -191.8% |
| Net margin | -26.0% | 17.2% | 49.6% | 46.2% | -0.8% | -238.6% | -3998.5% | -177.9% |
Company news
Coming soonHeadlines for CTMX will appear here once the news feed is connected.
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | Ogden Christopher· Chief Financial Officer | Sale | 1,624 | $3.05 | $4,953.20 | filing |
| 2026-03-17 | McCarthy Sean A.· CEO | Sale | 118,969 | $6.42 | $764,137.89 | filing |
| 2026-03-17 | BELVIN MARCIA· SVP, Chief Scientific Officer | Sale | 31,492 | $6.42 | $202,273.12 | filing |
| 2026-03-17 | Chu Yu-Waye· Chief Medical Officer | Sale | 21,279 | $6.42 | $136,675.02 | filing |
| 2026-03-17 | Ogden Christopher· Chief Financial Officer | Sale | 19,323 | $6.42 | $124,111.63 | filing |
| 2026-02-02 | BELVIN MARCIA· SVP, Chief Scientific Officer | Award | 60,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | Lester Rachael· Chief Business Officer | Award | 20,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | Chu Yu-Waye· Chief Medical Officer | Award | 75,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | Ogden Christopher· Chief Financial Officer | Award | 90,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | McCarthy Sean A.· CEO | Award | 210,000 | $0.00 | $0.00 | filing |
| 2025-11-06 | McCarthy Sean A.· CEO | Sale | 101,793 | $4.54 | $461,906.10 | filing |
| 2025-06-16 | McCarthy Sean A.· CEO | Sale | 55,511 | $2.69 | $149,263.53 | filing |
| 2025-06-16 | BELVIN MARCIA· SVP, Chief Scientific Officer | Sale | 13,884 | $2.69 | $37,334.08 | filing |
| 2025-06-16 | Ogden Christopher· Chief Financial Officer | Sale | 10,614 | $2.69 | $28,539.98 | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.